Tofacitinib Citrate Sustained?Release Tablets (gujie) – Wholesale & Retail (For Research Use Only)

描述

Each tablet contains 11?mg tofacitinib citrate in a sustained?release matrix designed to achieve stable plasma concentration over 24 hours. Tofacitinib is a selective Janus kinase (JAK1 and JAK3) inhibitor, disrupting inflammatory cytokine signaling pathways. Clinically used for autoimmune conditions like rheumatoid arthritis, psoriasis, and ulcerative colitis, in research these tablets serve to explore immune signaling, cytokine regulation, transplant rejection models, and chronic inflammatory mechanisms. Manufactured by CSPC Ouyi Pharmaceutical Co., Ltd. under Chinese approval H20223760, available in 14?tablet bottles or boxes. Strictly for laboratory research only.

Tofacitinib Citrate Sustained?Release Tablets Product Specifications

Tofacitinib Citrate Sustained?Release Tablets Mechanism of Action & Research Applications

Tofacitinib citrate functions as a JAK1/JAK3 inhibitor, blocking downstream STAT activation and reducing signaling from pro-inflammatory cytokines. This mechanism is valuable in laboratory research modeling rheumatoid arthritis, ulcerative colitis, psoriasis, transplant rejection, and JAK?STAT pathway studies. The sustained-release formulation enables consistent exposure, supporting chronic dosing protocols and pharmacokinetics research in vitro or animal models.

Tofacitinib Citrate Sustained?Release Tablets Side Effects (For Reference Only in Research Models)

Experimental or clinical-analogue models may present increased infection markers due to immunosuppression, elevated blood pressure, changes in lipid profiles, gastrointestinal issues, headache, and rare thromboembolic events. These observations inform safety-first design in research dosing regimens.

Disclaimer

Tofacitinib Citrate Sustained?Release Tablets 11?mg are strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.